Scarica l'app Stockscreener
17.84
3.04%
-0.56
Trevi Therapeutics Inc Borsa (TRVI) Ultime notizie
Trevi Therapeutics Targets Refractory Chronic Cough With Fresh Phase 2 Trial - TipRanks
SG Americas Securities LLC Decreases Stock Position in Trevi Therapeutics, Inc. $TRVI - MarketBeat
TRVi stock stays tied to Trevi Therapeutics' clinical outlook - ad-hoc-news.de
Price to sales forward of Trevi Therapeutics, Inc. – NASDAQ:TRVI - TradingView
Price to book forward of Trevi Therapeutics, Inc. – NASDAQ:TRVI - TradingView
Price to earnings forward of Trevi Therapeutics, Inc. – BOATS:TRVI - TradingView
Trevi Therapeutics stock hits all-time high at 19.33 USD By Investing.com - Investing.com South Africa
Trevi Therapeutics stock hits all-time high at 19.33 USD - Investing.com
$Trevi Therapeutics (TRVI.US)$ keep squeezing baby - Moomoo
Should Trevi’s Multi‑Index Russell Exit Reshape How Haduvio Drives the Trevi Therapeutics (TRVI) Story? - simplywall.st
Trevi Therapeutics, Inc.(NasdaqGM: TRVI) dropped from Russell 3000E Growth Benchmark - marketscreener.com
Trevi Therapeutics, Inc.(NasdaqGM: TRVI) dropped from Russell Microcap Index - marketscreener.com
Trevi Therapeutics, Inc.(NasdaqGM: TRVI) dropped from Russell 3000E Index - marketscreener.com
Trevi Therapeutics, Inc.(NasdaqGM:TRVI) dropped from Russell Microcap Growth Benchmark Index - marketscreener.com
A Quick Look at Today's Ratings for Trevi Therapeutics(TRVI.US), With a Forecast Between $18 to $23 - Moomoo
Trevi Therapeutics stock hits all-time high at 18.17 USD By Investing.com - Investing.com Australia
Trevi Therapeutics stock hits all-time high at 18.17 USD - Investing.com
Trevi Therapeutics, Inc. Actuals & Estimates (NASDAQ:TRVI) - TradingView
TRVI Forecast — Price Target — Prediction for 2027 - TradingView
Trevi Therapeutics Inc (TRVI) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
$Trevi Therapeutics (TRVI.US)$ finally you are getting squeezed - Moomoo
Trevi Therapeutics Inc (TRVI) Valuation: PE, PB & Fair Value Analysis - TradingKey
Trevi Therapeutics Inc (TRVI) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Trevi Therapeutics Inc (TRVI) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Trevi Therapeutics Inc (TRVI) Institutional Confidence - TradingKey
Trevi Therapeutics Inc (TRVI) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Trevi Therapeutics Inc (TRVI) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Trevi Therapeutics stock hits all-time high at 16.13 USD By Investing.com - Investing.com Nigeria
Trevi Therapeutics Inc (TRVI) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Trevi Therapeutics Inc (TRVI) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Trevi Therapeutics Announces Upcoming June and July Event Schedule - GlobeNewswire
Trevi Therapeutics stock hits all-time high at 16.13 USD - Investing.com
Trevi Therapeutics Slides As Hot Biotech Rally Cools - TipRanks
Trevi Therapeutics (TRVI) Surges 5.05% as Momentum Builds Near ResistanceBox Spread - dars.gov.et
128,306,056 Common Stock of Trevi Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 16-JUN-2026. - marketscreener.com
Certain Stock Options of Trevi Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 16-JUN-2026. - marketscreener.com
Certain Warrants of Trevi Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 16-JUN-2026. - marketscreener.com
TRVI Q1 2026 Earnings: Clinical Progress Drives Stock Gains Despite EPS MissEarnings Call Q&A - newsline.com
Trevi Therapeutics Shareholders Approve Stock and Governance Changes - The Globe and Mail
Trevi Therapeutics (TRVI) director receives 35,000-share stock option grant - Stock Titan
Trevi Therapeutics (TRVI) doubles authorized stock, adds 8,000,000-plan shares - Stock Titan
[Form 4] Trevi Therapeutics, Inc. Insider Trading Activity - Stock Titan
Trevi Therapeutics (TRVI) director receives 35K nonstatutory option grant - Stock Titan
Director at Trevi Therapeutics (NASDAQ: TRVI) awarded 35,000 stock options - Stock Titan
Director at Trevi Therapeutics (TRVI) receives 35,000 stock options award - Stock Titan
Trevi Therapeutics Inc Annual Shareholders Meeting Transcript - GuruFocus
Trevi Therapeutics Is Up 100%, Pivotal bioVenture Adds Anyway. Here's Why That Matters. - AOL.com
TRVI: All proposals passed, including share increase and director election, with no shareholder questions - TradingView
Pivotal bioVenture Partners Increases Trevi Therapeutics Holdings by 296,944 Shares in Q1 2026News and Statistics - IndexBox
Trevi Therapeutics stock hits 52-week low at 13.68 USD By Investing.com - Investing.com Canada
Trevi Therapeutics stock hits 52-week low at 13.68 USD - Investing.com
TRVI Q1 2026 Earnings: Wider-than-Expected Loss as Clinical-Stage Biotech Advances PipelineProfit Growth Outlook - newsline.com
Trevi Therapeutics (TRVI) Holds Near Resistance After Modest GainNew Highs New Lows - The Legal Advocate
Trevi Therapeutics (TRVI) Shows Potential as Shares Climb Over 2%OBV Divergence - thelegaladvocate.com
TRVITrevi Therapeutics Inc Options - Finviz
Cantor Fitzgerald Initiates Coverage of Trevi Therapeutics (TRVI) with Overweight Recommendation - MSN
2.64%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):